Article preview reprinted from IN VIVO - February/March, 2010
Alliance dollars were low in January, with only three biopharma deals reaching a potential deal value of $100 million or more, led by Ipsen and Inspiration's collaboration in hemophilia, worth $518 million. The bigger M&A dollars were seen in the device and diagnostic sectors, including Medtronic's take-out of CV device firm Invatec and its affiliates for $500 million. Both biopharma and device financing were down compared with December. Read more...
Deals in Depth: January 2010
Article preview reprinted from IN VIVO - February/March, 2010
Our monthly overview of dealmaking in the biopharmaceutical, medical device and in vitro diagnostics industries.
January 2010 dealmaking highlights:
Alliance dollars were low in January, with only three biopharma deals reaching a potential deal value of $100 million or more. Leading those was Ipsen and Inspiration's collaboration in hemophilia, worth $518 million.The bigger M&A dollars were seen in the device and diagnostic sectors. Medtronic paid $500 million for CV device firm Invatec and its affiliates. Meanwhile Inverness did a pair of $200 million-plus takeovers—POC tester and partner Epocal and the partial acquisition of Korean company Standard Diagnostics. Both biopharma and device financing were down compared with December. Once again, money from follow-ons, particularly the financing from AMAG, fueled the total invested in drug companies.
- Amanda Micklus
Purchase this article online as a PDF and receive it immediately via email. Questions? Call (800) 332-2181. 100% Satisfaction Guaranteed.
Medical device manufacturers facing many challenges: from the rising clout of group purchasing organizations (GPOs) to payment bundling and physicians' growing allegiance with hospitals in product price negotiations. Get all the answers now in new Medtech Insight's new 24-page Special Report: Medical Device Landscape: How regulatory changes and cost control measures are reshaping the industry. Availible for purchase now!
Limited-time offer: Single-incision laparoscopy or natural orifice surgery: Which will win the day, or is there room for both? Are You Ready For The New Scarless Surgery Revolution? Download you FREE report now
Companies mentioned in this article
Digital Biotech Co. Ltd.
Epocal Inc.
Inspiration Biopharmaceuticals Inc.
International Vitamin Corp.
Inverness Medical Nutritionals Group
Inverness Medical Innovations Inc.
Standard Diagnostics Inc.
Ipsen
Johnson & Johnson
LifeScan Inc.
Animas Corp.
Juvenile Diabetes Research Foundation
Kirin Holdings Co. Ltd.
Kyowa Hakko Kirin Co. Ltd.
Krauth medical KG
Martek Biosciences Corp.
Amerifit Brands Inc.
Medtronic Inc.
Invatec SRL
Krauth Cardiovascular GMBH
Merz GMBH & Co. KGAA
Merz Aesthetics US
Merz Pharmaceuticals GMBH
Quidel Corp.
Diagnostic Hybrids Inc.
Reata Pharmaceuticals Inc.
Roche
Sonova Holding AG
InSound Medical Inc.
Subscribe to IN VIVO.
IN VIVO delivers:
- Revealing, in-depth coverage of your competitors' strategies
- Incisive projections of future industry trends and their implications for your business
- Expert analysis of key industry developments
- Exclusive interviews with top industry executives and analysts
- In-depth examination of dealmaking, marketing, R&D, regulatory, and finance strategies -- those that were successful and those that missed the mark




.jpg)


Comments